|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | SDX105 | Storage (From the date of receipt) |
3 years -20°C powder | |||||||||||
| 化学式 | C16H21Cl2N3O2
|
||||||||||||||
| 分子量 | 358.26 | CAS No. | 16506-27-7 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO | 72 mg/mL (200.97 mM) | ||||||||||||
| Ethanol | 7 mg/mL (19.53 mM) | ||||||||||||||
| Water | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | Bendamustine is a nitrogen mustard drug used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. |
|---|
| KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas [ Cancers (Basel), 2025, 17(12)2034] | PubMed: 40563683 |
| DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways [ Front Immunol, 2024, 15:1470328] | PubMed: 39380995 |
| Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents [ Br J Haematol, 2024, 10.1111/bjh.19658] | PubMed: 39080847 |
| Patient-derived rhabdomyosarcoma cells recapitulate the genetic and transcriptomic landscapes of primary tumors [ iScience, 2024, 27(10):110862] | PubMed: 39319271 |
| Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells [ PLoS One, 2024, 19(9):e0309533] | PubMed: 39348376 |
| Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment [ BMC Pharmacol Toxicol, 2024, 25(1):25] | PubMed: 38444002 |
| Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment [ BMC Pharmacol Toxicol, 2024, 25(1):25] | PubMed: 38444002 |
| Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia [ Sci Rep, 2023, 13(1):16950] | PubMed: 37805613 |
| Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia [ Sci Rep, 2023, 13(1):16950] | PubMed: 37805613 |
| The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma [ Hematol Oncol, 2022, 10.1002/hon.3007] | PubMed: 35439335 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。